Artrya Limited (ASX: AYA) - ETF Exposure

Current share price for AYA : $4.990 0.21 (4.39%)⁺

Artrya Limited (AYA) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a company engaged in the development and commercialisation of a patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease.

AYA General Information ⁺

ASX Code	AYA
Website	http://www.artrya.com
Industry/Sector	Health Care Technology
Market Cap ($M)	813
AYA Share Price	$4.990
Day High	$5.060
Day Low	$4.700
Last Close	$4.780
AYA Share Price Movement	$0.21 ( 4.39% )

Prices as at 16:35, 27 Aug 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Already own an Australian ETF? You may already have meaningful exposure to AYA

Artrya Limited (AYA) is held across 2 ETFs spanning strategies that include health care technology exposure . Its weighting in those funds means performance can have an outsized influence - when AYA moves, funds like ATEC and VAS that hold it can move with it.

For more concentrated exposure, ETFs such as ATEC (BetaShares S&P/ASX Australian Technology ETF) allocate about 0.8% to AYA , while the average exposure across all 2 ETFs that hold it is around 0.4% .

Top ETF holdings

BetaShares S&P/ASX Australian Technology ETF (ATEC) ~ 0.8%
Vanguard Australian Shares Index ETF (VAS) ~ 0%

Last updated: ETF data and holdings as at 26 August 2026

Own AYA directly or through an ETF?

How does holding Artrya Limited (AYA) shares directly compare to ETFs that include it?

	AYA Direct	ATEC ASX	VAS ASX
Holdings	1 company	46 holdings	318 holdings
AYA Weight	100%	0.8%	0%
Diversification	Single Stock	Broad	Broad
Annual Cost	Brokerage only	0.48% p.a.	0.07% p.a.
Approx. Yield	0%	1.78%	2.89%
Star Ratings	-

Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not AYA's direct yield. Annual cost uses each ETF's MER.

AYA Exposure on $10,000 investment

How a $10,000 investment in Artrya Limited (AYA) one week ago compares with ETFs that hold it.

Security	Investment type	Current price	7-day price movement	Dollar change	Value today
Artrya Limited (AYA)	Direct share	$4.990	7.31%	+$731	$10,731
BetaShares S&P/ASX Australian Technology ETF (ATEC)	Equity - Australia Sectors	$23.130	-1.99%	-$199	$9,801
Vanguard Australian Shares Index ETF (VAS)	Equity - Australia	$112.480	-0.04%	-$4	$9,996

Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.

Artrya Limited (AYA) ETFs

2 ETFs hold Artrya Limited (AYA).

ETF	AYA Weight	MER	Yield
BetaShares S&P/ASX Australian Technology ETF (ATEC)	0.8%	0.48%	1.78%
Vanguard Australian Shares Index ETF (VAS)	0%	0.07%	2.89%

Artrya Limited (AYA) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Artrya Limited (AYA) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Artrya Limited (AYA) price-sensitive announcements

AYA - Appendix 4E and Annual Report to Shareholders

Artrya Limited's Annual Report for the financial year ending 30 June 2026 highlights a net

Artrya Limited (AYA)
19 Aug 2026 | 11:16 AM

AYA - June Quarterly Activities Report and Appendix 4C

Artrya Limited reported on its activities and financial performance for the quarter ending

Artrya Limited (AYA)
29 Jul 2026 | 8:37 AM

AYA - Northeast Georgia Health System goes live with Salix

Artrya Limited, an Australian medical technology company, has successfully launched its Sa

Artrya Limited (AYA)
23 Jul 2026 | 8:30 AM

AYA - March Quarterly Activities Report and Appendix 4C

Artrya Limited reported significant progress in the commercial roll-out of its Salix® AI-p

Artrya Limited (AYA)
30 Apr 2026 | 9:15 AM

Artrya Limited (AYA) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Application for quotation of securities - AYA	27 Aug 2026 5:03PM	$4.990	$4.990	fallen by 0%
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Issue of Shares on Exercise of Securities &Cleansing Notice	27 Aug 2026 4:57PM	$4.990	$4.990	fallen by 0%
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Application for quotation of securities - AYA	25 Aug 2026 7:03PM	$4.730	$4.990	risen by 5.50%
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Issue of Shares on Exercise of Securities & Cleansing Notice	25 Aug 2026 7:03PM	$4.730	$4.990	risen by 5.50%
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Appointment of Non-Executive Director - Helen Kurincic	20 Aug 2026 7:59AM	$4.650	$4.990	risen by 7.31%
Artrya Limited (AYA) ORDINARY FULLY PAID	Health Care	$813	Appendix 4G	19 Aug 2026 11:28AM	$4.690	$4.990	risen by 6.40%

AYA Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$5.00	-70.50%	0.00%	0.0%
2026A	-$25.18	-$17.00	-4.50%	0.00%	0.0%
2025A	-$16.41	-$17.80	-0.20%	0.00%	0.0%

AYA Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 A	2027 F	2025 A	2026 A	2027 F	2025 A	2026 A	2027 F
4DMedical Limited (4DX)	$2,328M	0.3304	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Artrya Limited (AYA)	$771M	-0.0450	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Pro Medicus Limited (PME)	$19,912M	1.3034	-0.2811	0.2395	75.1577	104.5472	84.3437	0.36%	0.49%	0.60%

AYA Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	9.95	0.00
Market	0.35	13.20	1.16	0.86
Sector	0.66	20.00	1.68	3.51

AYA Directors

Name	Position	Start Date
Mr Bernard (Bernie) William Ridgeway	Non-Executive Chairman, Non-Executive Director	8 Feb 2021
Ms Helen Kurincic	Non-Executive Director	20 Aug 2026
Dr Jacque Sokolov	Non-Executive Director	1 Aug 2022
Ms Catherine (Kate) Hill	Non-Executive Director	22 Feb 2023
Dr Jeffrey LeBenger	Non-Executive Director	18 Feb 2026

Artrya Limited (AYA) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
18 Jun 2026	RIDGEWAY, Bernard (Bernie)	Exercise	Options	750,000	$1.000	$750,000.000
18 Jun 2026	RIDGEWAY, Bernard (Bernie)	Buy	Indirect Shares	750,000	$1.000	$750,000.000
11 Jun 2026	RIDGEWAY, Bernard (Bernie)	Sell	Indirect Shares	300,000	$4.600	$1,380,000.000

See all changes in directors' interest & trades for Artrya Limited (AYA) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

AYA Management

Name	Position
Mark Edward Pitts	Company Secretary

AYA Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Artrya Limited (AYA). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
13,206,395 (8.91%)	Regal Funds Management Pty Limited

AYA Calendar of Events

Date	Event
18 August 2027	Report (Annual)
18 August 2027	Report (Prelim)
24 February 2027	Report (Interim)
27 August 2026	Issued Shares

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us